**Lay Descriptions of Important Outcomes**

We have identified a novel compound with RON inhibitor activity and expected specificity for RON. Pharmacokinetic testing of this compound has now been completed. We are currently in the process of planning the next steps to move forward with preclinical testing of this compound in mouse models of breast cancer metastasis. Data from these studies are anticipated to inform the development of this compound into a potential new treatment strategy for metastatic breast cancer patients.